Inhibition of HIV-1 Tat-Dependent Trans Activation by Steric Block Chimeric 2‘-O-Methyl/LNA Oligoribonucleotides†
Identifieur interne : 003466 ( Main/Exploration ); précédent : 003465; suivant : 003467Inhibition of HIV-1 Tat-Dependent Trans Activation by Steric Block Chimeric 2‘-O-Methyl/LNA Oligoribonucleotides†
Auteurs : Andrey Arzumanov [Danemark] ; Andrew P. Walsh [Danemark] ; Vivek K. Rajwanshi [Danemark] ; Ravindra Kumar [Danemark] ; Jesper Wengel [Danemark] ; Michael J. Gait [Danemark, Royaume-Uni]Source :
- Biochemistry [ 0006-2960 ] ; 2001.
Descripteurs français
- KwdFr :
- ARN viral (), ARN viral (antagonistes et inhibiteurs), ARN viral (métabolisme), Activation de la transcription (), Amorces ADN (), Cations (métabolisme), Cellules HeLa, Conformation d'acide nucléique, Fluorescéines, Fragments peptidiques (), Fragments peptidiques (métabolisme), Humains, Luciferases (métabolisme), Métabolisme des lipides, Oligonucléotides antisens (pharmacologie), Produits du gène tat du virus de l'immunodéficience humaine, Protéines du gène tat (antagonistes et inhibiteurs), Protéines du gène tat (génétique), Répétition terminale longue du VIH, Spectrométrie de masse MALDI, Transcription génétique, Transfection, Tétracycline (métabolisme), VIH-1 (Virus de l'Immunodéficience Humaine de type 1) (génétique).
- MESH :
- antagonistes et inhibiteurs : ARN viral, Protéines du gène tat.
- génétique : Protéines du gène tat, VIH-1 (Virus de l'Immunodéficience Humaine de type 1).
- métabolisme : ARN viral, Cations, Fragments peptidiques, Luciferases, Tétracycline.
- pharmacologie : Oligonucléotides antisens.
- ARN viral, Activation de la transcription, Amorces ADN, Cellules HeLa, Conformation d'acide nucléique, Fluorescéines, Fragments peptidiques, Humains, Métabolisme des lipides, Produits du gène tat du virus de l'immunodéficience humaine, Répétition terminale longue du VIH, Spectrométrie de masse MALDI, Transcription génétique, Transfection.
English descriptors
- KwdEn :
- Cations (metabolism), DNA Primers (chemistry), Fluoresceins, Gene Products, tat (antagonists & inhibitors), Gene Products, tat (genetics), HIV Long Terminal Repeat, HIV-1 (genetics), HeLa Cells, Humans, Lipid Metabolism, Luciferases (metabolism), Nucleic Acid Conformation, Oligonucleotides, Antisense (pharmacology), Peptide Fragments (chemistry), Peptide Fragments (metabolism), RNA, Viral (antagonists & inhibitors), RNA, Viral (chemistry), RNA, Viral (metabolism), Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization, Tetracycline (metabolism), Transcription, Genetic, Transcriptional Activation (drug effects), Transfection, tat Gene Products, Human Immunodeficiency Virus.
- MESH :
- chemical , antagonists & inhibitors : Gene Products, tat, RNA, Viral.
- chemical , chemistry : DNA Primers, Peptide Fragments, RNA, Viral.
- chemical , genetics : Gene Products, tat.
- chemical , metabolism : Cations, Luciferases, Peptide Fragments, RNA, Viral, Tetracycline.
- chemical , pharmacology : Oligonucleotides, Antisense.
- chemical : Fluoresceins, tat Gene Products, Human Immunodeficiency Virus.
- drug effects : Transcriptional Activation.
- genetics : HIV-1.
- HIV Long Terminal Repeat, HeLa Cells, Humans, Lipid Metabolism, Nucleic Acid Conformation, Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization, Transcription, Genetic, Transfection.
Abstract
The HIV-1 trans-activation responsive element (TAR) RNA 59-residue stem−loop interacts with the HIV trans-activator protein Tat and other cellular factors to stimulate transcriptional elongation from the viral long terminal repeat (LTR). Inhibition of these interactions blocks full-length HIV transcription and hence replication. We have found that three types of 12-residue oligonucleotide analogues, namely, a 2‘-O-methyl oligoribonucleotide (OMe), a chimeric oligonucleotide containing 7×OMe and 5×5-methyl C locked nucleic acid (LNA) residues, and a peptide nucleic acid (PNA), inhibit Tat-dependent in vitro transcription in HeLa cell nuclear extract equally efficiently (50% inhibition at 100−200 nM) and sequence specifically. The results are correlated with surprisingly similar binding strengths to a model 39-residue TAR under transcription conditions. A 12-mer containing 11 contiguous LNA residues was less effective in both Tat-dependent transcription inhibition and TAR 39 binding. Anti-TAR 3‘-carboxyfluorescein- (FAM-) labeled OMe and OMe/LNA chimeric 12-mers were also efficient Tat-dependent in vitro transcription inhibitors as were 3‘-FAM-labeled OMe oligonucleotides containing some phosphorothioate (PS) linkages. By use of a HeLa cell line containing stably integrated plasmids expressing firefly luciferase under HIV-LTR/Tat dependence as well as a Renilla luciferase constitutive control, we showed submicromolar, selective, dose-dependent, and sequence-dependent intracellular inhibition of Tat-TAR trans activation by the anti-TAR 3‘-FAM 12-residue 7×OMe/5×LNA oligonucleotide when delivered by cationic lipid. No intracellular activity was observed for the corresponding anti-TAR 3‘-FAM OMe 12-mer. An alternating PS-containing 3‘-FAM OMe 12-mer oligonucleotide exhibited partial inhibition of trans-activation activity, but this was correlated with a similar effect on control gene expression, suggesting nonspecific inhibition.
Url:
DOI: 10.1021/bi011279e
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream Istex, to step Corpus: 000616
- to stream Istex, to step Curation: 000616
- to stream Istex, to step Checkpoint: 000D88
- to stream PubMed, to step Corpus: 002530
- to stream PubMed, to step Curation: 002530
- to stream PubMed, to step Checkpoint: 002408
- to stream Ncbi, to step Merge: 000116
- to stream Ncbi, to step Curation: 000116
- to stream Ncbi, to step Checkpoint: 000116
- to stream Main, to step Merge: 003504
- to stream Main, to step Curation: 003466
Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title>Inhibition of HIV-1 Tat-Dependent Trans Activation by Steric Block Chimeric 2‘-O-Methyl/LNA Oligoribonucleotides†</title><author><name sortKey="Arzumanov, Andrey" sort="Arzumanov, Andrey" uniqKey="Arzumanov A" first="Andrey" last="Arzumanov">Andrey Arzumanov</name></author><author><name sortKey="Walsh, Andrew P" sort="Walsh, Andrew P" uniqKey="Walsh A" first="Andrew P." last="Walsh">Andrew P. Walsh</name></author><author><name sortKey="Rajwanshi, Vivek K" sort="Rajwanshi, Vivek K" uniqKey="Rajwanshi V" first="Vivek K." last="Rajwanshi">Vivek K. Rajwanshi</name></author><author><name sortKey="Kumar, Ravindra" sort="Kumar, Ravindra" uniqKey="Kumar R" first="Ravindra" last="Kumar">Ravindra Kumar</name></author><author><name sortKey="Wengel, Jesper" sort="Wengel, Jesper" uniqKey="Wengel J" first="Jesper" last="Wengel">Jesper Wengel</name></author><author><name sortKey="Gait, Michael J" sort="Gait, Michael J" uniqKey="Gait M" first="Michael J." last="Gait">Michael J. Gait</name></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:AAEB2A3C128C5341CC21BFE6BE11295C790DA9FE</idno><date when="2001" year="2001">2001</date><idno type="doi">10.1021/bi011279e</idno><idno type="url">https://api.istex.fr/ark:/67375/TPS-CF21QVHP-5/fulltext.pdf</idno><idno type="wicri:Area/Istex/Corpus">000616</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Corpus" wicri:corpus="ISTEX">000616</idno><idno type="wicri:Area/Istex/Curation">000616</idno><idno type="wicri:Area/Istex/Checkpoint">000D88</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Checkpoint">000D88</idno><idno type="wicri:doubleKey">0006-2960:2001:Arzumanov A:inhibition:of:hiv</idno><idno type="wicri:source">PubMed</idno><idno type="RBID">pubmed:11724578</idno><idno type="wicri:Area/PubMed/Corpus">002530</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">002530</idno><idno type="wicri:Area/PubMed/Curation">002530</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">002530</idno><idno type="wicri:Area/PubMed/Checkpoint">002408</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">002408</idno><idno type="wicri:Area/Ncbi/Merge">000116</idno><idno type="wicri:Area/Ncbi/Curation">000116</idno><idno type="wicri:Area/Ncbi/Checkpoint">000116</idno><idno type="wicri:doubleKey">0006-2960:2001:Arzumanov A:inhibition:of:hiv</idno><idno type="wicri:Area/Main/Merge">003504</idno><idno type="wicri:Area/Main/Curation">003466</idno><idno type="wicri:Area/Main/Exploration">003466</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main">Inhibition of HIV-1 Tat-Dependent <hi rend="italic">Trans</hi> Activation by Steric Block Chimeric
2‘-<hi rend="italic">O</hi>-Methyl/LNA Oligoribonucleotides<ref type="bib" target="#bi011279eAF2"><hi rend="superscript">†</hi></ref></title><author><name sortKey="Arzumanov, Andrey" sort="Arzumanov, Andrey" uniqKey="Arzumanov A" first="Andrey" last="Arzumanov">Andrey Arzumanov</name><affiliation wicri:level="1"><country xml:lang="fr">Danemark</country><wicri:regionArea>Laboratory of Molecular Biology, Medical Research Council, Hills Road, Cambridge CB2 2QH, U.K.,Department of Chemistry, University of Copenhagen, DK-2100 Copenhagen, Denmark, and Department of Chemistry,University of Southern Denmark, DK-5230 Odense M</wicri:regionArea><wicri:noRegion>DK-5230 Odense M</wicri:noRegion></affiliation><affiliation></affiliation><affiliation></affiliation></author><author><name sortKey="Walsh, Andrew P" sort="Walsh, Andrew P" uniqKey="Walsh A" first="Andrew P." last="Walsh">Andrew P. Walsh</name><affiliation wicri:level="1"><country xml:lang="fr">Danemark</country><wicri:regionArea>Laboratory of Molecular Biology, Medical Research Council, Hills Road, Cambridge CB2 2QH, U.K.,Department of Chemistry, University of Copenhagen, DK-2100 Copenhagen, Denmark, and Department of Chemistry,University of Southern Denmark, DK-5230 Odense M</wicri:regionArea><wicri:noRegion>DK-5230 Odense M</wicri:noRegion></affiliation><affiliation></affiliation><affiliation></affiliation></author><author><name sortKey="Rajwanshi, Vivek K" sort="Rajwanshi, Vivek K" uniqKey="Rajwanshi V" first="Vivek K." last="Rajwanshi">Vivek K. Rajwanshi</name><affiliation wicri:level="1"><country xml:lang="fr">Danemark</country><wicri:regionArea>Laboratory of Molecular Biology, Medical Research Council, Hills Road, Cambridge CB2 2QH, U.K.,Department of Chemistry, University of Copenhagen, DK-2100 Copenhagen, Denmark, and Department of Chemistry,University of Southern Denmark, DK-5230 Odense M</wicri:regionArea><wicri:noRegion>DK-5230 Odense M</wicri:noRegion></affiliation><affiliation></affiliation></author><author><name sortKey="Kumar, Ravindra" sort="Kumar, Ravindra" uniqKey="Kumar R" first="Ravindra" last="Kumar">Ravindra Kumar</name><affiliation wicri:level="1"><country xml:lang="fr">Danemark</country><wicri:regionArea>Laboratory of Molecular Biology, Medical Research Council, Hills Road, Cambridge CB2 2QH, U.K.,Department of Chemistry, University of Copenhagen, DK-2100 Copenhagen, Denmark, and Department of Chemistry,University of Southern Denmark, DK-5230 Odense M</wicri:regionArea><wicri:noRegion>DK-5230 Odense M</wicri:noRegion></affiliation><affiliation></affiliation></author><author><name sortKey="Wengel, Jesper" sort="Wengel, Jesper" uniqKey="Wengel J" first="Jesper" last="Wengel">Jesper Wengel</name><affiliation wicri:level="1"><country xml:lang="fr">Danemark</country><wicri:regionArea>Laboratory of Molecular Biology, Medical Research Council, Hills Road, Cambridge CB2 2QH, U.K.,Department of Chemistry, University of Copenhagen, DK-2100 Copenhagen, Denmark, and Department of Chemistry,University of Southern Denmark, DK-5230 Odense M</wicri:regionArea><wicri:noRegion>DK-5230 Odense M</wicri:noRegion></affiliation><affiliation></affiliation></author><author><name sortKey="Gait, Michael J" sort="Gait, Michael J" uniqKey="Gait M" first="Michael J." last="Gait">Michael J. Gait</name><affiliation wicri:level="1"><country xml:lang="fr">Danemark</country><wicri:regionArea>Laboratory of Molecular Biology, Medical Research Council, Hills Road, Cambridge CB2 2QH, U.K.,Department of Chemistry, University of Copenhagen, DK-2100 Copenhagen, Denmark, and Department of Chemistry,University of Southern Denmark, DK-5230 Odense M</wicri:regionArea><wicri:noRegion>DK-5230 Odense M</wicri:noRegion></affiliation><affiliation></affiliation><affiliation wicri:level="1"><country wicri:rule="url">Royaume-Uni</country></affiliation></author></analytic><monogr></monogr><series><title level="j" type="main">Biochemistry</title><title level="j" type="abbrev">Biochemistry</title><idno type="ISSN">0006-2960</idno><idno type="eISSN">1520-4995</idno><imprint><publisher>American Chemical Society</publisher><date type="e-published">2001</date><date type="published">2001</date><biblScope unit="vol">40</biblScope><biblScope unit="issue">48</biblScope><biblScope unit="page" from="14645">14645</biblScope><biblScope unit="page" to="14654">14654</biblScope></imprint><idno type="ISSN">0006-2960</idno></series></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0006-2960</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Cations (metabolism)</term><term>DNA Primers (chemistry)</term><term>Fluoresceins</term><term>Gene Products, tat (antagonists & inhibitors)</term><term>Gene Products, tat (genetics)</term><term>HIV Long Terminal Repeat</term><term>HIV-1 (genetics)</term><term>HeLa Cells</term><term>Humans</term><term>Lipid Metabolism</term><term>Luciferases (metabolism)</term><term>Nucleic Acid Conformation</term><term>Oligonucleotides, Antisense (pharmacology)</term><term>Peptide Fragments (chemistry)</term><term>Peptide Fragments (metabolism)</term><term>RNA, Viral (antagonists & inhibitors)</term><term>RNA, Viral (chemistry)</term><term>RNA, Viral (metabolism)</term><term>Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization</term><term>Tetracycline (metabolism)</term><term>Transcription, Genetic</term><term>Transcriptional Activation (drug effects)</term><term>Transfection</term><term>tat Gene Products, Human Immunodeficiency Virus</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>ARN viral ()</term><term>ARN viral (antagonistes et inhibiteurs)</term><term>ARN viral (métabolisme)</term><term>Activation de la transcription ()</term><term>Amorces ADN ()</term><term>Cations (métabolisme)</term><term>Cellules HeLa</term><term>Conformation d'acide nucléique</term><term>Fluorescéines</term><term>Fragments peptidiques ()</term><term>Fragments peptidiques (métabolisme)</term><term>Humains</term><term>Luciferases (métabolisme)</term><term>Métabolisme des lipides</term><term>Oligonucléotides antisens (pharmacologie)</term><term>Produits du gène tat du virus de l'immunodéficience humaine</term><term>Protéines du gène tat (antagonistes et inhibiteurs)</term><term>Protéines du gène tat (génétique)</term><term>Répétition terminale longue du VIH</term><term>Spectrométrie de masse MALDI</term><term>Transcription génétique</term><term>Transfection</term><term>Tétracycline (métabolisme)</term><term>VIH-1 (Virus de l'Immunodéficience Humaine de type 1) (génétique)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="antagonists & inhibitors" xml:lang="en"><term>Gene Products, tat</term><term>RNA, Viral</term></keywords><keywords scheme="MESH" type="chemical" qualifier="chemistry" xml:lang="en"><term>DNA Primers</term><term>Peptide Fragments</term><term>RNA, Viral</term></keywords><keywords scheme="MESH" type="chemical" qualifier="genetics" xml:lang="en"><term>Gene Products, tat</term></keywords><keywords scheme="MESH" type="chemical" qualifier="metabolism" xml:lang="en"><term>Cations</term><term>Luciferases</term><term>Peptide Fragments</term><term>RNA, Viral</term><term>Tetracycline</term></keywords><keywords scheme="MESH" type="chemical" qualifier="pharmacology" xml:lang="en"><term>Oligonucleotides, Antisense</term></keywords><keywords scheme="MESH" type="chemical" xml:lang="en"><term>Fluoresceins</term><term>tat Gene Products, Human Immunodeficiency Virus</term></keywords><keywords scheme="MESH" qualifier="antagonistes et inhibiteurs" xml:lang="fr"><term>ARN viral</term><term>Protéines du gène tat</term></keywords><keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>Transcriptional Activation</term></keywords><keywords scheme="MESH" qualifier="genetics" xml:lang="en"><term>HIV-1</term></keywords><keywords scheme="MESH" qualifier="génétique" xml:lang="fr"><term>Protéines du gène tat</term><term>VIH-1 (Virus de l'Immunodéficience Humaine de type 1)</term></keywords><keywords scheme="MESH" qualifier="métabolisme" xml:lang="fr"><term>ARN viral</term><term>Cations</term><term>Fragments peptidiques</term><term>Luciferases</term><term>Tétracycline</term></keywords><keywords scheme="MESH" qualifier="pharmacologie" xml:lang="fr"><term>Oligonucléotides antisens</term></keywords><keywords scheme="MESH" xml:lang="en"><term>HIV Long Terminal Repeat</term><term>HeLa Cells</term><term>Humans</term><term>Lipid Metabolism</term><term>Nucleic Acid Conformation</term><term>Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization</term><term>Transcription, Genetic</term><term>Transfection</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>ARN viral</term><term>Activation de la transcription</term><term>Amorces ADN</term><term>Cellules HeLa</term><term>Conformation d'acide nucléique</term><term>Fluorescéines</term><term>Fragments peptidiques</term><term>Humains</term><term>Métabolisme des lipides</term><term>Produits du gène tat du virus de l'immunodéficience humaine</term><term>Répétition terminale longue du VIH</term><term>Spectrométrie de masse MALDI</term><term>Transcription génétique</term><term>Transfection</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract">The HIV-1 trans-activation responsive element (TAR) RNA 59-residue stem−loop interacts with the HIV trans-activator protein Tat and other cellular factors to stimulate transcriptional elongation from the viral long terminal repeat (LTR). Inhibition of these interactions blocks full-length HIV transcription and hence replication. We have found that three types of 12-residue oligonucleotide analogues, namely, a 2‘-O-methyl oligoribonucleotide (OMe), a chimeric oligonucleotide containing 7×OMe and 5×5-methyl C locked nucleic acid (LNA) residues, and a peptide nucleic acid (PNA), inhibit Tat-dependent in vitro transcription in HeLa cell nuclear extract equally efficiently (50% inhibition at 100−200 nM) and sequence specifically. The results are correlated with surprisingly similar binding strengths to a model 39-residue TAR under transcription conditions. A 12-mer containing 11 contiguous LNA residues was less effective in both Tat-dependent transcription inhibition and TAR 39 binding. Anti-TAR 3‘-carboxyfluorescein- (FAM-) labeled OMe and OMe/LNA chimeric 12-mers were also efficient Tat-dependent in vitro transcription inhibitors as were 3‘-FAM-labeled OMe oligonucleotides containing some phosphorothioate (PS) linkages. By use of a HeLa cell line containing stably integrated plasmids expressing firefly luciferase under HIV-LTR/Tat dependence as well as a Renilla luciferase constitutive control, we showed submicromolar, selective, dose-dependent, and sequence-dependent intracellular inhibition of Tat-TAR trans activation by the anti-TAR 3‘-FAM 12-residue 7×OMe/5×LNA oligonucleotide when delivered by cationic lipid. No intracellular activity was observed for the corresponding anti-TAR 3‘-FAM OMe 12-mer. An alternating PS-containing 3‘-FAM OMe 12-mer oligonucleotide exhibited partial inhibition of trans-activation activity, but this was correlated with a similar effect on control gene expression, suggesting nonspecific inhibition.</div></front></TEI><affiliations><list><country><li>Danemark</li><li>Royaume-Uni</li></country></list><tree><country name="Danemark"><noRegion><name sortKey="Arzumanov, Andrey" sort="Arzumanov, Andrey" uniqKey="Arzumanov A" first="Andrey" last="Arzumanov">Andrey Arzumanov</name></noRegion><name sortKey="Gait, Michael J" sort="Gait, Michael J" uniqKey="Gait M" first="Michael J." last="Gait">Michael J. Gait</name><name sortKey="Kumar, Ravindra" sort="Kumar, Ravindra" uniqKey="Kumar R" first="Ravindra" last="Kumar">Ravindra Kumar</name><name sortKey="Rajwanshi, Vivek K" sort="Rajwanshi, Vivek K" uniqKey="Rajwanshi V" first="Vivek K." last="Rajwanshi">Vivek K. Rajwanshi</name><name sortKey="Walsh, Andrew P" sort="Walsh, Andrew P" uniqKey="Walsh A" first="Andrew P." last="Walsh">Andrew P. Walsh</name><name sortKey="Wengel, Jesper" sort="Wengel, Jesper" uniqKey="Wengel J" first="Jesper" last="Wengel">Jesper Wengel</name></country><country name="Royaume-Uni"><noRegion><name sortKey="Gait, Michael J" sort="Gait, Michael J" uniqKey="Gait M" first="Michael J." last="Gait">Michael J. Gait</name></noRegion></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/MersV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 003466 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 003466 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= MersV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= ISTEX:AAEB2A3C128C5341CC21BFE6BE11295C790DA9FE
|texte= Inhibition of HIV-1 Tat-Dependent Trans Activation by Steric Block Chimeric 2‘-O-Methyl/LNA Oligoribonucleotides†
}}
| This area was generated with Dilib version V0.6.33. |  |